SCHEMBL1703065

SCHEMBL1703065

Nc1n[nH]c2ccnc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 1.00
KIT P10721 9/20 0.77
FLT3 P36888 9/20 0.77
FLT1 P17948 7/20 0.71
CSF1R P07333 6/20 0.71
LCK P06239 6/20 0.71
LYN P07948 6/20 0.71
FLT4 P35916 6/20 0.71
BLK P51451 6/20 0.71
FYN P06241 5/20 0.71
ROCK2 O75116 3/20 0.71
EPHA2 P29317 3/20 0.71
NTRK2 Q16620 3/20 0.71
AURKB Q96GD4 3/20 0.71
PLK4 O00444 2/20 0.71
ITK Q08881 2/20 0.71
AURKA O14965 2/20 0.71
CHEK2 O96017 2/20 0.71
NTRK1 P04629 2/20 0.71
RPS6KA3 P51812 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424715 0.87 KDR (1.00) KDRKITFLT3FLT1CSF1R
SCHEMBL1703611 0.87 KDR (0.78) KDRKITFLT3FLT1CSF1R
SCHEMBL2238731 0.86 KDR (0.75) KDRKITFLT3FLT1CSF1R
SCHEMBL1702780 0.86 KDR (0.77) KDRKITFLT3FLT1CSF1R
SCHEMBL2237406 0.86 KDR (0.78) KDRKITFLT3FLT1CSF1R
SCHEMBL1702977 0.85 KDR (0.75) KDRKITFLT3FLT1CSF1R
SCHEMBL1703314 0.85 KDR (1.00) KDRKITFLT3FLT1CSF1R
SCHEMBL1703112 0.85 KDR (0.83) KDRKITFLT3FLT1CSF1R
SCHEMBL1702788 0.85 KDR (0.76) KDRKITFLT3FLT1CSF1R
SCHEMBL2237945 0.84 KDR (0.75) KDRKITFLT3FLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885FLT3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.